RT Journal Article
SR Electronic
T1 High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-related Acute Respiratory Distress Syndrome: A Multicenter and Randomized Open-label Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21263597
DO 10.1101/2021.09.15.21263597
A1 Maskin, Luis Patricio
A1 Bonelli, Ignacio
A1 Olarte, Gabriel Leonardo
A1 Palizas, Fernando
A1 Velo, Agostina E
A1 Lurbet, María Fernanda
A1 Lovazzano, Pablo
A1 Kotsias, Sophia
A1 Attie, Shiry
A1 Saubidet, Ignacio Lopez
A1 Baredes, Natalio D
A1 Setten, Mariano
A1 Rodriguez, Pablo Oscar
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.15.21263597.abstract
AB Purpose To determine whether high-dose dexamethasone increases the number of ventilator-free days (VFD) among patients with acute respiratory distress syndrome due to coronavirus disease 2019 (C-ARDS)Materials A multicenter randomized controlled trial in adults with C-ARDS. Patients received 16 mg/d of dexamethasone intravenously for five days followed by 8 mg/d of dexamethasone for five days, or 6 mg/d of dexamethasone intravenously for 10 days.Results Data from 98 patients who received at least one dose of dexamethasone were analyzed. At 28 days after randomization, there was no difference between high- and low-dose dexamethasone groups in VFD (median, 0 d [interquartile range (IQR) 0–14 d] versus 0 d [IQR 0–1 d]; P=0.231). The cumulative hazard of successful discontinuation from mechanical ventilation was increased by the high-dose treatment (adjusted sub-distribution hazard ratio: 1.84; 95% CI: 1.31 to 2.5; P<0.001). None of the prespecified secondary and safety outcomes showed a significant difference between treatment arms.Conclusions Among patients with C-ARDS, the use of higher doses of dexamethasone compared with the recommended low-dose treatment did not show an increase in VFD. However, the higher dose significantly improved the time required to liberate them from the ventilatorClinical Trial Registered: NCT04395105Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04395105Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectorsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved at the Research Ethics Committee of CEMIC (Buenos Aires, Argentina) and by the Argentine Society of Intensive Care Medicine (SATI) Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesxI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data will be available upon request